Sunday, December 18, 2016 6:34:09 AM
SPONSORED Think in-vitro fertilization is out of your budget? A new system promises a more natural process for a fraction of the cost.
According to the CDC, infertility affects around one in 10 American couples. However, nearly half of these couples aren’t seeking treatment or are unable to access it. Why? The main barrier to traditional in-vitro fertilization (IVF) methods is the cost in both money and time.
IVF can cost anywhere from $11-13,000 per cycle, with many couples undergoing multiple cycles. The means the average cost per baby born ends up being around $41,000, a staggering amount of money that represents a large chunk of the average American family’s take-home income. So, why is IVF so expensive?
A big production
IVF is normally a complex process involving numerous factors that drive up the cost. Because of the expense of infrastructure, specialized labor and materials needed, many IVF centers have a large overhead.
Traditional IVF uses incubators which need CO2, oxygen, and electricity to run, and must be monitored 24/7 to prevent accidents. Because many particles in the air can be toxic to embryos, IVF labs must create meticulously controlled environments to prevent contamination.
In practice, traditional IVF physicians use a high-stimulation protocol, where women are given large doses of hormone medication to pump up their egg production. Not only are these medications expensive, especially when used so liberally, but actually put patients at risk of developing ovarian hyperstimulation syndrome, in which the ovaries become swollen and painful.
Most couples will be required to make five or more visits to the doctor, which further drives up the cost. Additionally, many patients are losing time that they could be working and sometimes travelling long distances to reach the nearest IVF center.
“In our minds, INVOcell felt more comfortable and allowed us to feel more in control of having a baby.”
A simpler alternative
Thankfully, a new system called INVOcell by INVO Bioscience promises to eliminate a lot of the time, labor, and expense associated with traditional treatments by using a simpler and more natural method.
When eggs are retrieved, they are not manipulated in any way before being placed, along with sperm, in a small polystyrene capsule similar to a cryopreservation tube. Instead of being placed in a CO2 incubator, the capsule is inserted intra-vaginally (in-vivo) where fertilization and embryo development occur.
Because the woman’s body acts as a natural incubator, the costs of maintaining machines and staff necessary to monitor embryo development are reduced. The female body also creates a more stable environment that fluctuates with the mother’s body rhythms, just as in natural conception.
The INVO method also uses low ovary stimulation, meaning fewer expensive drugs and may lead to a healthier and potentially less painful process for the women who go through it.
Fertility to the people
The INVOcell system not only cuts costs in half (sometimes more) but it also makes treatment possible anywhere, decreases doctors visits and allows couples to feel more involved in the process. “In our minds, INVOcell felt more comfortable and allowed us to feel more in control of having a baby,” says INVO patient April Crow.
Instead of being taken away to a lab, the embryo is immediately returned to the woman in the INVOcell device, which mitigates the fears of an embryo mix-up. Additionally, conception within the mother’s body may better align with the religious beliefs of parents.
In a clinical trial of 450 cycles, pregnancy rates were statistically the same as traditional IVF and the process has gotten the endorsement of the American Society for Reproductive Medicine. “The success rate of INVO versus traditional IVF is equivalent,” says Dr. Kevin Doody of Effortless IFV, who uses the system at his facility, “There’s really no difference.”
INVO Bioscience’s mission with this new system is to get proper care to those who need it. Fertility is a part of reproductive health, and that should be a right for all people. By letting nature do the work, INVO is democratizing IVF and making it possible for more people to experience the miracle of childbirth.
http://www dot futureofpersonalhealth.com/sponsored/a-new-ivf-method-brings-fertility-to-the-people
Recent INVO News
- Micro Cap Massively Bid Up Before Opening Bell • AllPennyStocks.com • 04/17/2024 02:25:00 PM
- INVO Reports Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 04/16/2024 08:59:29 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/06/2024 03:24:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 02:01:07 PM
- NAYA Biosciences To Acquire Clinical Stage Gene Therapy Program for Leber's Hereditary Optic Neuropathy (LHON) • GlobeNewswire Inc. • 01/23/2024 01:00:00 PM
- INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors • GlobeNewswire Inc. • 01/17/2024 01:00:00 PM
- Form S-4 - Registration of securities, business combinations • Edgar (US Regulatory) • 01/16/2024 10:29:59 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 01/10/2024 09:46:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2024 09:05:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/03/2024 10:29:45 PM
- Form 424B7 - Prospectus [Rule 424(b)(7)] • Edgar (US Regulatory) • 12/28/2023 10:04:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 10:02:41 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 12/13/2023 10:08:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/13/2023 09:53:21 PM
- NAYA Biosciences Announces Publication of New Data for its CD38-targeted Flex-NK™ Bispecific Antibody in the American Society of Hematology's Blood Journal • PR Newswire (US) • 12/11/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/28/2023 10:18:38 PM
- INVO Bioscience Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement • PR Newswire (US) • 11/28/2023 02:00:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/24/2023 06:08:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 09:59:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 09:10:41 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:06:04 PM
- INVO Reports Record Third Quarter 2023 Financial Results • PR Newswire (US) • 11/13/2023 09:01:00 PM
- Form SC TO-C - Written communication relating to an issuer or third party • Edgar (US Regulatory) • 11/13/2023 02:23:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 02:21:54 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/13/2023 02:12:34 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM